COMMUNIQUÉS West-GlobeNewswire

Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer
28/09/2026
- Stable or increased weight was twice as common among pancreatic cancer patients in the atebimetinib + mGnP study, compared to those in a benchmark study - - Patients with stable or increased weight at three months had [...]
Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer
28/09/2026
Dr. Houvras brings over two decades of executive leadership across premier industry and academic research institutions in clinical development, translational medicine and immuno-oncology WALTHAM, Mass., Sept. 28, 2026 ( [...]
SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247
28/09/2026
BARDA partnership accelerates development of SCY-247 as a potential therapy for the treatment and prevention of serious invasive fungal infections, addressing a critical public health need Non-dilutive funding for SCY- [...]
U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
28/09/2026
NDA submission completed following positive Phase 3 SELVA results; potential U.S. commercial launch in the first half of 2027, if approved QTORIN™ rapamycin has the potential to become the first FDA-approved therapy and [...]
CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit
28/09/2026
New 50 mg tablet formulation delivers an improved pharmacokinetic profile and enables greater exposure and patient convenience FDA removal of the prior drug exposure limit provides greater dosing flexibility in future [...]
Inventiva publie ses résultats financiers non audités du premier semestre 2026 et fait le point sur ses activités
28/09/2026
Trésorerie et équivalents de trésorerie à 166,1 millions d’euros et dépôts à court terme 1 à 67,8 millions d’euros au 30 juin 2026 Horizon de trésorerie inchangé par rapport au 30 juillet 2026 2 Résultats principaux de [...]
Inventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate Update
28/09/2026
Cash and cash equivalents at €166.1 million and €67.8 million in short-term deposits 1 as of June 30, 2026 Cash runway guidance remains unchanged from July 30, 2026 2 Topline results of the Phase 3 NATiV3 clinical trial [...]
Unlocking the Growth - Invitation to BioPorto’s investor meeting on October 7
28/09/2026
September 28, 2026 News release Unlocking the Growth - Invitation to BioPorto’s investor meeting on October 7 As BioPorto continues to advance its commercial strategy and capitalize on emerging clinical opportunities, [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
28/09/2026
COPENHAGEN, Denmark, September 28, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an [...]
Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Granted Orphan Drug Designation in Japan, Further Expanding Global Regulatory Recognition
28/09/2026
NANJING, China, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that opamtistomig (LBL-024), the Company’s proprietary PD‑L1/4‑ [...]
Thermo Fisher Scientific and Evosep Enter Reseller Agreement for Evosep Eno
28/09/2026
Thermo Fisher Scientific to offer the Evosep Eno separation platform to customers, expanding access to standardized, high-throughput proteomics workflows SINGAPORE, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Evosep™, a global [...]
A New International Medical Approach Aimed at Reversing Diabetes has Officially Launched in Shenzhen, China
28/09/2026
SHENZHEN, China, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Recently in Shenzhen, China, the Center for Integrative Medicine for Chronic Diseases and the Center for Natural Diabetes Therapy at Shenzhen Hengsheng Hospital—a [...]
Penn Medicine et IBA lancent une joint-venture pour accompagner le développement de la protonthérapie et des programmes de radio-oncologie dans le monde
28/09/2026
Une nouvelle offre de services d’experts afin d’aider les établissements de santé à développer, déployer et optimiser leurs programmes de protonthérapie et de radio-oncologie sur l’ensemble des soins PHILADELPHIE, [...]
Penn Medicine and IBA Launch Joint Venture to Advance Proton Therapy and Radiation Oncology Program Development Worldwide
28/09/2026
New expert-led services platform will help healthcare providers develop, implement, and optimize proton therapy and advanced radiation oncology programs across the full care delivery lifecycle PHILADELPHIA, Pa., and [...]
Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update
28/09/2026
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 28, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small [...]
JJP Biologics to Present Data Showing the Potential of Nebaprubart for Linear IgA Dermatosis (LAD) at Two Key Upcoming Scientific Conferences
28/09/2026
Positive interim data from Phase Ib proof-of-concept trial will be presented at the IPPF Scientific Symposium on Pemphigus and Pemphigoid and at EADV Congress 2026 Data positions nebaprubart as a potential therapy [...]
OSE Immunotherapeutics publie sa position de trésorerie au 30 juin 2026 et fait un point sur ses activités
28/09/2026
11,1 millions d’euros de trésorerie au 30 juin 2026 ; horizon de financement confirmé jusqu’à fin décembre 2026 La Société poursuit activement ses interactions avec les investisseurs institutionnels aux États-Unis et en [...]
OSE Immunotherapeutics Reports its Cash Position as of June 30, 2026, and Provides Business Update
28/09/2026
€11.1 million cash position as of June 30, 2026; cash runway confirmed through December 2026 The Company continues to engage actively with institutional investors in the United States and Europe to extend its cash [...]
HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors
28/09/2026
First-in-class KRAS-payload leveraging synchronized EGFR inhibition HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 27, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ” or the “Company”) (Nasdaq/AIM: [...]

Pages